Formulary Watch |

All News - Page 22

GSK’s Arexvy is First RSV Vaccine Approved for Older Adults
GSK’s Arexvy is First RSV Vaccine Approved for Older Adults
GSK’s Arexvy is First RSV Vaccine Approved for Older Adults
May 4, 2023
In June, the Advisory Committee on Immunization Practices (ACIP) will make recommendations on the appropriate use of the vaccine in the U.S.
Two FDA Approvals for Expanded Pediatric Indications
Two FDA Approvals for Expanded Pediatric Indications
Two FDA Approvals for Expanded Pediatric Indications
May 3, 2023
Cystic fibrosis drug Trikafta gets expanded indication for children ages 2-5.
Avadel Says New Narcolepsy Med Will be Priced Competitively
Avadel Says New Narcolepsy Med Will be Priced Competitively
Avadel Says New Narcolepsy Med Will be Priced Competitively
May 2, 2023
Despite having a highly differentiated clinical value proposition compared to branded, twice-nightly oxybates, Avadel is pricing Lumryz at $64.67 per gram or around $177,034 annually, which is on par with twice-nightly oxybate products that require chronic, middle-of-the-night awakening.
Patients Often Lose in the Battle between Pharma and PBMs
Patients Often Lose in the Battle between Pharma and PBMs
Patients Often Lose in the Battle between Pharma and PBMs
May 2, 2023
Over the last five years, both PBMs and drug manufacturers have implemented restrictions that put more of the costs for specialty medications on patients.
FDA Clears Two Schizophrenia Meds
FDA Clears Two Schizophrenia Meds
FDA Clears Two Schizophrenia Meds
May 1, 2023
Uzedy’s wholesale acquisition cost (WAC) ranges from $1,232 to $3,080 per month.
FDA Approves First Fecal Microbiota Pill for Recurrent C. diff Infection
FDA Approves First Fecal Microbiota Pill for Recurrent C. diff Infection
FDA Approves First Fecal Microbiota Pill for Recurrent C. diff Infection
April 28, 2023
CDI is a leading cause of infections acquired in healthcare settings, including hospitals and nursing homes. After recovering, individuals may get the infection again, and the risk of recurrence increases with each infection.
FDA OKs First-of-its-Kind Treatment for Rare Form of ALS
FDA OKs First-of-its-Kind Treatment for Rare Form of ALS
FDA OKs First-of-its-Kind Treatment for Rare Form of ALS
April 27, 2023
The list price for Qalsody, the first and only approved treatment to target a genetic cause of ALS, may prove to be controversial.
54% of Top-Selling Medicare Drugs Rated as Low-Benefit, Study Finds
54% of Top-Selling Medicare Drugs Rated as Low-Benefit, Study Finds
54% of Top-Selling Medicare Drugs Rated as Low-Benefit, Study Finds
April 26, 2023
The study found that Medicare patients used low-benefit options more frequently than high-benefit options.
Hospital Group Assails AHIP’s Drug Price Report
Hospital Group Assails AHIP’s Drug Price Report
Hospital Group Assails AHIP’s Drug Price Report
April 25, 2023
The American Hospital Association said the health insurers' report on drug prices, which highlights the higher prices charged by hospitals, is “a blatant attempt to deflect from the obvious — insurance companies continue to raise premiums for their enrollees and employer clients while pocketing billions in profit.”
AbbVie Snags New Chronic Migraine Indication for Qulipta
AbbVie Snags New Chronic Migraine Indication for Qulipta
AbbVie Snags New Chronic Migraine Indication for Qulipta
April 24, 2023
Qulipta (atogepant) produced $158 million last year in net revenues in the U.S. as a preventive agent for episodic migraines.
FDA Requires New Warnings For Prescription Opioids in Another Step to Prevent Overdoses
FDA Requires New Warnings For Prescription Opioids in Another Step to Prevent Overdoses
FDA Requires New Warnings For Prescription Opioids in Another Step to Prevent Overdoses
April 21, 2023
One of the warnings regard the risk of opioid-induced hyperalgesia, a condition associated with taking opioids that causes an increase in pain or an increased sensitivity to pain.
Express Scripts Expands Independent Pharmacy in Rural Healthcare
Express Scripts Expands Independent Pharmacy in Rural Healthcare
Express Scripts Expands Independent Pharmacy in Rural Healthcare
April 20, 2023
The expansion offers increased reimbursement opportunities and additional care services to rural independent pharmacies. In addition, it creates an Independent Pharmacy Advisory Committee to expand the role of rural, suburban and urban pharmacies in the healthcare system.
FDA Approves Omisirge to Reduce Infection Risk in Blood Cancer Patients Undergoing Stem Cell Transplant
FDA Approves Omisirge to Reduce Infection Risk in Blood Cancer Patients Undergoing Stem Cell Transplant
FDA Approves Omisirge to Reduce Infection Risk in Blood Cancer Patients Undergoing Stem Cell Transplant
April 19, 2023
Omisirge is a stem cell therapy that helps the body recover more quickly from cancer treatments that kill normal blood cells along with blood cancer cells, thus lowering the risk of infection.
FDA Clears Rizafilm to Treat Acute Migraine
FDA Clears Rizafilm to Treat Acute Migraine
FDA Clears Rizafilm to Treat Acute Migraine
April 19, 2023
The film version may be well-suited for many patients who have migraine-related nausea, says the president of the company that developed the medication.
  FDA Declines to Approve Lilly’s Ulcerative Colitis Drug
  FDA Declines to Approve Lilly’s Ulcerative Colitis Drug
FDA Declines to Approve Lilly’s Ulcerative Colitis Drug
April 17, 2023
The FDA cited issues related to the proposed manufacturing of the drug, mirikizumab. Lilly expressed confidence that they could be corrected.
HyQvia Receives Expanded FDA Approval for Pediatric Primary Immunodeficiency
HyQvia Receives Expanded FDA Approval for Pediatric Primary Immunodeficiency
HyQvia Receives Expanded FDA Approval for Pediatric Primary Immunodeficiency
April 14, 2023
HyQvia is the first FDA-approved treatment for primary immunodeficiency (PI) available as a once-a-month subcutaneous injection. Other treatments for PI, while similarly effective, present a greater burden to patients, often requiring more frequent injections or more invasive routes of administration
New Express Scripts Programs Aim to Boost Affordability, Transparency
New Express Scripts Programs Aim to Boost Affordability, Transparency
New Express Scripts Programs Aim to Boost Affordability, Transparency
April 13, 2023
Through Express Scripts’ new Copay Assurance plan, consumers will have lower out-of-pocket costs because of caps on prescription drugs: $5 for generics, $25 for preferred brand drugs, and $45 for preferred specialty brand drugs.
U.S. Payers May Find Tirzepatide Costs Acceptable Given the Treatment Benefits in Patients with Type 2 Diabetes
U.S. Payers May Find Tirzepatide Costs Acceptable Given the Treatment Benefits in Patients with Type 2 Diabetes
U.S. Payers May Find Tirzepatide Costs Acceptable Given the Treatment Benefits in Patients with Type 2 Diabetes
April 12, 2023
Tirzepatide was associated with a greater reduction in hemoglobin A1c and body weight versus semaglutide. Though, with a current list price of $1,023 for a one-month supply of tirzepatide (Mounjaro; Lilly), is it worth it?
AbbVie Withdraws Two Blood Cancer Indications From Imbruvica
AbbVie Withdraws Two Blood Cancer Indications From Imbruvica
AbbVie Withdraws Two Blood Cancer Indications From Imbruvica
April 11, 2023
Other indications for the blockbuster cancer mediation are not affected.
Healthcare Groups, Legislators Slam Texas Mifepristone Ruling
Healthcare Groups, Legislators Slam Texas Mifepristone Ruling
Healthcare Groups, Legislators Slam Texas Mifepristone Ruling
April 10, 2023
This case and a case in Washington state are likely to be appealed to the Supreme Court.
FDA Officially Withdraws Makena, the Only Preterm Birth Med
FDA Officially Withdraws Makena, the Only Preterm Birth Med
FDA Officially Withdraws Makena, the Only Preterm Birth Med
April 7, 2023
Issued jointly by the FDA Commissioner and Chief Scientist, the decision means Makena and its generics are no longer approved and cannot lawfully be distributed in interstate commerce. At the same time, the agency “recognizes that there is a supply of product that has already been distributed.”
FDA Grants Emergency Use Authorization to Gohibic for Critically Ill COVID-19 Patients
FDA Grants Emergency Use Authorization to Gohibic for Critically Ill COVID-19 Patients
FDA Grants Emergency Use Authorization to Gohibic for Critically Ill COVID-19 Patients
April 6, 2023
The FDA granted the EUA based on the PANAMO phase 3 clinical trial results demonstrating that vilobelimab improved survival compared to placebo, with a 23.9% relative reduction in all-cause mortality at 28 days.
FDA Grants Accelerated Approval for Padcev - Keytruda Combo
FDA Grants Accelerated Approval for Padcev - Keytruda Combo
FDA Grants Accelerated Approval for Padcev - Keytruda Combo
April 5, 2023
The combination of Padcev with Merck’s Keytruda has a potentially large market: approximately 8,000 to 9,000 U.S. patients would be eligible for this combination in the U.S.
Could Copay Assistance Narrow Health Inequities?
Could Copay Assistance Narrow Health Inequities?
Could Copay Assistance Narrow Health Inequities?
April 4, 2023
A study funded by Genentech showed that the assistance programs substantially reduce prescription abandonment regardless of race or income level.
New York Launches PBM for Medicaid Beneficiaries
New York Launches PBM for Medicaid Beneficiaries
New York Launches PBM for Medicaid Beneficiaries
April 3, 2023
State officials say the new NYRx program will mean fewer restrictions and create a largest pharmacy network in the state.
New Insulin Cap Bill Lauded, But Caution Urged
New Insulin Cap Bill Lauded, But Caution Urged
New Insulin Cap Bill Lauded, But Caution Urged
March 31, 2023
A bipartisan Senate bill, Affordable Insulin Now Act of 2023, would require plans to cover insulin for no more than $35 per month.
Second Senate Committee Heaps Criticism on PBMs
Second Senate Committee Heaps Criticism on PBMs
Second Senate Committee Heaps Criticism on PBMs
March 30, 2023
Members of the Senate Finance Committee want to modernize the rules around PBM business practices to lower out-of-pocket costs and increase competition.
 FDA Clears Narcan OTC for Opioid Overdoses
 FDA Clears Narcan OTC for Opioid Overdoses
FDA Clears Narcan OTC for Opioid Overdoses
March 29, 2023
Emergent BioSolutions hasn’t provided a price for the nonprescription Narcan but said the product will be available by late summer.
FDA Schedules Advisory Committee Meeting for OTC Contraceptive
FDA Schedules Advisory Committee Meeting for OTC Contraceptive
FDA Schedules Advisory Committee Meeting for OTC Contraceptive
March 29, 2023
If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.
© 2024 MJH Life Sciences

All rights reserved.